Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials.

Fiche publication

Date publication

mai 2018

Journal

British journal of clinical pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr SCHMITT Antonin

Tous les auteurs :
Schmitt A, Nguyen L, Zorza G, Ferré P, Pétain A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29341179

Résumé

Vinflunine is a novel tubulin-targeted inhibitor indicated as a single agent for the treatment of bladder cancers after failure of prior platinum-based therapy. Its pharmacokinetics (PK) and pharmacodynamics (PD) have been independently characterized through several phase I and phase II studies. However, no global pharmacometric analysis had been conducted as yet.